european dermaportation patent, page-23

Hi Pman,
If reality pans out anywhere close to the scenario I expect, a PR machine roll out at the moment would be counter productive.

Share price has not been brought to appropriate levels to prepare the somewhat delicate news we might hear soon.
Glyn very much knows that investors are invested for the reason of international partnering activities.
Our own product commercialisation would have to be spiced up with international connections ( UK ) in place and within a broader commercialisation effort from the partnering companies regarding their programs.
I expect therefore our own product news to be garnished with complimentary updates from our partners bringing it all into perspective.


In our recent upside down, back to front OBJ sentiment predicament I expect the next leg up in share price shortly. 1.3 cent has been captured, next stop should see us clearing 1.5 cent on our way to 2 cents to be ready for our own
product development progress report ( I see price hitting 2 cents within this month ).


The recently hired product manager would be nearing conclusion, our own program has triggered positive response from testing in Europe.


From the annual report:

The company is also actively developing its own product portfolio to provide commercial flexability in controlling our " own products " that may provide an opportunity for early commercialisation for the Company.
The company had previously announced that it had chosen the musculoskeletal and pain patch sectors as the first product offerings.
Developments moved another step forward with UK-based consumer and concept research data indicating commercial opportunities for both initiatives.
Expanded new product concept testing was initiate during the period to help define the product needs in the international market.



Fair to say, we are nearing news regarding this development.
In conjunction with latest indicators for a CR down the track I expect strong buying pressure to appear soonish.

What we have seen so far was the bounce off the bottom and the next waves should be introduced soon.


Ever since reading the annual report OBJ's own product development took the number one spot within program timelines.




This will guarantee the milestone issuance of performance shares for the directors in time to be loaded when an actual partnering development comes online.
Since directors are prohibited from insider trading with exclusive knowledge of how things will unfold, these performance shares issued through our own product/s hitting the commercialisation phase function as the getting loaded factor for management....and rightly so, I might add.

This brings me back to Southoz's stated confusion of my latest bounce in sentiment, claiming a short term sell on the heels of a pump in the making ( in my personal scenario), a short term buy for most in the market and finally a medium term buy due to the proven tech, the scenario described above and the partnering contract ready to eventually make landfall, 2 years late I assume, but nevertheless rerating OBJ to levels unimaginable in the moment, as I see it.